Wendy Armstrong
Concepts (371)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 68 | 2026 | 3193 | 5.630 |
Why?
| | Epidemics | 7 | 2026 | 96 | 2.220 |
Why?
| | Communicable Diseases | 8 | 2023 | 166 | 1.820 |
Why?
| | Anti-Retroviral Agents | 5 | 2019 | 251 | 1.630 |
Why?
| | Anti-HIV Agents | 14 | 2026 | 912 | 1.540 |
Why?
| | Viral Load | 14 | 2026 | 526 | 1.150 |
Why?
| | Infectious Disease Medicine | 2 | 2017 | 12 | 1.040 |
Why?
| | Continuity of Patient Care | 5 | 2022 | 297 | 0.960 |
Why?
| | AIDS-Related Opportunistic Infections | 5 | 2019 | 130 | 0.870 |
Why?
| | HIV | 13 | 2023 | 251 | 0.870 |
Why?
| | Internal Medicine | 3 | 2016 | 279 | 0.860 |
Why?
| | Social Stigma | 2 | 2024 | 172 | 0.820 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 2 | 2019 | 20 | 0.740 |
Why?
| | Internship and Residency | 6 | 2021 | 1267 | 0.680 |
Why?
| | Pre-Exposure Prophylaxis | 3 | 2024 | 269 | 0.640 |
Why?
| | Drug Monitoring | 2 | 2016 | 401 | 0.640 |
Why?
| | Antiretroviral Therapy, Highly Active | 6 | 2019 | 279 | 0.620 |
Why?
| | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2020 | 19 | 0.620 |
Why?
| | Adenine | 2 | 2020 | 339 | 0.610 |
Why?
| | Diagnostic Tests, Routine | 2 | 2021 | 107 | 0.600 |
Why?
| | Acquired Immunodeficiency Syndrome | 7 | 2022 | 237 | 0.590 |
Why?
| | Humans | 97 | 2026 | 145474 | 0.580 |
Why?
| | Consumer Advocacy | 1 | 2018 | 12 | 0.560 |
Why?
| | United States | 27 | 2026 | 16098 | 0.540 |
Why?
| | Career Choice | 3 | 2018 | 234 | 0.540 |
Why?
| | Lost to Follow-Up | 2 | 2017 | 20 | 0.540 |
Why?
| | HIV-1 | 8 | 2026 | 908 | 0.520 |
Why?
| | Delivery of Health Care | 4 | 2021 | 946 | 0.510 |
Why?
| | Health Policy | 3 | 2023 | 400 | 0.500 |
Why?
| | Health Services Accessibility | 4 | 2024 | 1101 | 0.500 |
Why?
| | CD4 Lymphocyte Count | 6 | 2020 | 280 | 0.480 |
Why?
| | Georgia | 10 | 2024 | 79 | 0.470 |
Why?
| | Substance-Related Disorders | 6 | 2021 | 1102 | 0.470 |
Why?
| | Medication Adherence | 2 | 2017 | 540 | 0.460 |
Why?
| | Rilpivirine | 2 | 2026 | 10 | 0.450 |
Why?
| | Antimicrobial Stewardship | 3 | 2023 | 130 | 0.440 |
Why?
| | Disease Management | 1 | 2019 | 653 | 0.440 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 1 | 2014 | 9 | 0.430 |
Why?
| | Urban Population | 1 | 2017 | 493 | 0.410 |
Why?
| | Biomedical Research | 2 | 2018 | 717 | 0.410 |
Why?
| | Bone Diseases | 1 | 2014 | 61 | 0.400 |
Why?
| | Financing, Government | 1 | 2014 | 53 | 0.400 |
Why?
| | Metabolic Diseases | 1 | 2014 | 114 | 0.380 |
Why?
| | Drug Resistance, Viral | 2 | 2005 | 126 | 0.380 |
Why?
| | Patient Acceptance of Health Care | 2 | 2017 | 881 | 0.380 |
Why?
| | Rural Population | 1 | 2017 | 659 | 0.360 |
Why?
| | Ventriculostomy | 1 | 2012 | 24 | 0.360 |
Why?
| | Medication Errors | 1 | 2012 | 85 | 0.350 |
Why?
| | Chronic Pain | 3 | 2021 | 291 | 0.350 |
Why?
| | Central Nervous System Diseases | 1 | 2012 | 74 | 0.340 |
Why?
| | Mycoses | 1 | 2012 | 88 | 0.340 |
Why?
| | Ambulatory Care | 2 | 2021 | 609 | 0.330 |
Why?
| | Prostheses and Implants | 1 | 2012 | 137 | 0.330 |
Why?
| | Disease Transmission, Infectious | 1 | 2011 | 69 | 0.320 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2008 | 71 | 0.320 |
Why?
| | Critical Care | 1 | 2016 | 702 | 0.310 |
Why?
| | Cellulitis | 2 | 2011 | 54 | 0.310 |
Why?
| | Microbiology | 3 | 2014 | 24 | 0.310 |
Why?
| | Bacterial Infections | 1 | 2012 | 246 | 0.300 |
Why?
| | Physicians | 5 | 2019 | 955 | 0.300 |
Why?
| | Analgesics, Opioid | 5 | 2021 | 1149 | 0.300 |
Why?
| | Dermatitis | 1 | 2008 | 20 | 0.290 |
Why?
| | Medical Informatics | 1 | 2009 | 99 | 0.280 |
Why?
| | Patient-Centered Care | 1 | 2014 | 547 | 0.280 |
Why?
| | Male | 41 | 2026 | 72842 | 0.280 |
Why?
| | Female | 42 | 2026 | 78844 | 0.280 |
Why?
| | Global Health | 2 | 2018 | 403 | 0.280 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2008 | 49 | 0.280 |
Why?
| | Adult | 33 | 2026 | 40777 | 0.270 |
Why?
| | Education, Medical, Graduate | 5 | 2023 | 562 | 0.260 |
Why?
| | Africa, Eastern | 2 | 2017 | 12 | 0.260 |
Why?
| | Middle Aged | 32 | 2026 | 36215 | 0.260 |
Why?
| | Information Dissemination | 1 | 2009 | 224 | 0.260 |
Why?
| | Delayed Diagnosis | 2 | 2026 | 100 | 0.260 |
Why?
| | AIDS Vaccines | 2 | 2005 | 53 | 0.260 |
Why?
| | Periodicals as Topic | 1 | 2009 | 209 | 0.250 |
Why?
| | Viremia | 2 | 2026 | 160 | 0.240 |
Why?
| | Pneumonia, Pneumocystis | 4 | 2015 | 34 | 0.240 |
Why?
| | Developing Countries | 3 | 2017 | 316 | 0.240 |
Why?
| | Pyridones | 2 | 2026 | 209 | 0.230 |
Why?
| | Mycobacterium chelonae | 1 | 2005 | 8 | 0.230 |
Why?
| | Internet | 2 | 2014 | 689 | 0.230 |
Why?
| | Curriculum | 5 | 2023 | 1070 | 0.230 |
Why?
| | Databases, Factual | 2 | 2019 | 1490 | 0.220 |
Why?
| | Exosomes | 2 | 2016 | 104 | 0.210 |
Why?
| | Skin | 1 | 2008 | 753 | 0.200 |
Why?
| | Meningoencephalitis | 1 | 2003 | 24 | 0.190 |
Why?
| | Fellowships and Scholarships | 4 | 2023 | 354 | 0.190 |
Why?
| | Cost-Benefit Analysis | 3 | 2021 | 639 | 0.190 |
Why?
| | West Nile virus | 1 | 2003 | 41 | 0.190 |
Why?
| | Bacteria | 1 | 2008 | 765 | 0.190 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1581 | 0.180 |
Why?
| | Interviews as Topic | 2 | 2017 | 910 | 0.180 |
Why?
| | Anti-Infective Agents | 3 | 2015 | 232 | 0.180 |
Why?
| | Pain Management | 3 | 2021 | 410 | 0.180 |
Why?
| | Simulation Training | 1 | 2023 | 135 | 0.170 |
Why?
| | Colony-Stimulating Factors | 1 | 2001 | 37 | 0.170 |
Why?
| | Coronary Artery Bypass | 1 | 2003 | 268 | 0.170 |
Why?
| | Pandemics | 4 | 2026 | 1707 | 0.170 |
Why?
| | Erythrocyte Transfusion | 1 | 2003 | 225 | 0.170 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2005 | 339 | 0.160 |
Why?
| | Contact Tracing | 1 | 2020 | 26 | 0.160 |
Why?
| | Obesity | 1 | 2014 | 3116 | 0.160 |
Why?
| | Prescription Drug Misuse | 1 | 2021 | 52 | 0.160 |
Why?
| | Cities | 4 | 2022 | 138 | 0.160 |
Why?
| | Mass Screening | 2 | 2020 | 1360 | 0.160 |
Why?
| | Models, Theoretical | 2 | 2021 | 558 | 0.160 |
Why?
| | Erythropoietin | 1 | 2001 | 100 | 0.150 |
Why?
| | Registries | 2 | 2019 | 2406 | 0.150 |
Why?
| | Sexual and Gender Minorities | 1 | 2024 | 259 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2026 | 992 | 0.150 |
Why?
| | Policy | 1 | 2021 | 148 | 0.150 |
Why?
| | Life Expectancy | 1 | 2020 | 73 | 0.150 |
Why?
| | Interleukin-2 | 1 | 2001 | 440 | 0.150 |
Why?
| | Heart Diseases | 1 | 2022 | 341 | 0.150 |
Why?
| | Alanine | 1 | 2020 | 169 | 0.140 |
Why?
| | Fever of Unknown Origin | 1 | 1999 | 13 | 0.140 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2019 | 38 | 0.140 |
Why?
| | Cross-Sectional Studies | 5 | 2021 | 5904 | 0.140 |
Why?
| | Cohort Studies | 7 | 2019 | 6013 | 0.140 |
Why?
| | Health Equity | 1 | 2021 | 133 | 0.140 |
Why?
| | Mentors | 2 | 2018 | 217 | 0.140 |
Why?
| | Comorbidity | 2 | 2020 | 1661 | 0.140 |
Why?
| | Prevalence | 5 | 2024 | 2865 | 0.140 |
Why?
| | Microbial Sensitivity Tests | 3 | 2016 | 364 | 0.140 |
Why?
| | Tenofovir | 1 | 2020 | 301 | 0.130 |
Why?
| | Sexually Transmitted Diseases | 1 | 2020 | 168 | 0.130 |
Why?
| | Physician Assistants | 1 | 2019 | 101 | 0.130 |
Why?
| | Capital Financing | 1 | 2017 | 7 | 0.130 |
Why?
| | Patient Identification Systems | 1 | 2017 | 16 | 0.130 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 46 | 0.130 |
Why?
| | Nurse Practitioners | 1 | 2019 | 138 | 0.130 |
Why?
| | Africa | 1 | 2017 | 119 | 0.130 |
Why?
| | Risk Factors | 7 | 2020 | 10885 | 0.130 |
Why?
| | Hospitalization | 4 | 2020 | 2460 | 0.130 |
Why?
| | Anti-Bacterial Agents | 4 | 2011 | 1923 | 0.120 |
Why?
| | Financing, Personal | 1 | 2016 | 27 | 0.120 |
Why?
| | Research Personnel | 1 | 2018 | 184 | 0.120 |
Why?
| | Viral Tropism | 1 | 2016 | 36 | 0.120 |
Why?
| | Case Management | 1 | 2016 | 68 | 0.120 |
Why?
| | Motivation | 2 | 2017 | 600 | 0.110 |
Why?
| | Hospitals | 2 | 2021 | 732 | 0.110 |
Why?
| | Diketopiperazines | 2 | 2026 | 23 | 0.110 |
Why?
| | Opioid-Related Disorders | 2 | 2021 | 602 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 389 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 383 | 0.110 |
Why?
| | Drug Utilization Review | 1 | 2015 | 61 | 0.110 |
Why?
| | Organizational Policy | 1 | 2015 | 78 | 0.110 |
Why?
| | HIV Protease Inhibitors | 1 | 2015 | 69 | 0.110 |
Why?
| | Online Systems | 1 | 2014 | 20 | 0.110 |
Why?
| | Esophageal Diseases | 1 | 2015 | 30 | 0.110 |
Why?
| | Candidiasis | 1 | 2015 | 64 | 0.110 |
Why?
| | Cytosol | 1 | 2015 | 213 | 0.110 |
Why?
| | Time-to-Treatment | 1 | 2017 | 251 | 0.110 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2019 | 440 | 0.100 |
Why?
| | Patient Navigation | 1 | 2016 | 126 | 0.100 |
Why?
| | Alcoholism | 1 | 2021 | 822 | 0.100 |
Why?
| | Retrospective Studies | 8 | 2026 | 17291 | 0.100 |
Why?
| | Organophosphates | 1 | 2015 | 179 | 0.100 |
Why?
| | Drug Interactions | 1 | 2015 | 405 | 0.100 |
Why?
| | Healthcare Disparities | 1 | 2020 | 735 | 0.100 |
Why?
| | Ambulatory Care Facilities | 1 | 2016 | 269 | 0.100 |
Why?
| | Patient Readmission | 1 | 2019 | 769 | 0.100 |
Why?
| | DNA, Viral | 2 | 2012 | 356 | 0.090 |
Why?
| | Health Plan Implementation | 1 | 2014 | 141 | 0.090 |
Why?
| | Dihydropteroate Synthase | 2 | 2004 | 3 | 0.090 |
Why?
| | Medication Reconciliation | 1 | 2012 | 32 | 0.090 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 574 | 0.090 |
Why?
| | Incidence | 2 | 2021 | 2923 | 0.090 |
Why?
| | Oligopeptides | 1 | 2014 | 267 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 961 | 0.090 |
Why?
| | Pilot Projects | 2 | 2017 | 1891 | 0.090 |
Why?
| | HIV Antibodies | 1 | 2012 | 61 | 0.090 |
Why?
| | Myocardial Infarction | 2 | 2019 | 1210 | 0.090 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2953 | 0.090 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1323 | 0.090 |
Why?
| | Mycobacterium haemophilum | 1 | 2011 | 1 | 0.090 |
Why?
| | Primary Health Care | 2 | 2019 | 1735 | 0.090 |
Why?
| | Aged | 8 | 2022 | 26153 | 0.090 |
Why?
| | Parasitic Diseases | 1 | 2011 | 8 | 0.080 |
Why?
| | Research | 1 | 2014 | 430 | 0.080 |
Why?
| | Mycobacterium Infections | 1 | 2011 | 55 | 0.080 |
Why?
| | Cytomegalovirus | 1 | 2012 | 168 | 0.080 |
Why?
| | Pneumocystis | 2 | 2001 | 8 | 0.080 |
Why?
| | Catheter-Related Infections | 1 | 2012 | 96 | 0.080 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2011 | 93 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2019 | 1196 | 0.080 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2011 | 92 | 0.080 |
Why?
| | Health Care Costs | 1 | 2014 | 425 | 0.080 |
Why?
| | Geography | 1 | 2011 | 187 | 0.080 |
Why?
| | Cytokines | 2 | 2016 | 2067 | 0.080 |
Why?
| | Education, Medical, Undergraduate | 1 | 2013 | 207 | 0.080 |
Why?
| | Surveys and Questionnaires | 5 | 2023 | 6066 | 0.080 |
Why?
| | Cytomegalovirus Infections | 1 | 2012 | 206 | 0.080 |
Why?
| | Sulfonamides | 1 | 2014 | 583 | 0.080 |
Why?
| | Rectum | 1 | 2011 | 182 | 0.080 |
Why?
| | Pyridines | 1 | 2014 | 609 | 0.080 |
Why?
| | Antibodies, Neutralizing | 1 | 2012 | 340 | 0.070 |
Why?
| | Adolescent | 5 | 2021 | 22529 | 0.070 |
Why?
| | Desiccation | 1 | 2009 | 26 | 0.070 |
Why?
| | Deep Brain Stimulation | 1 | 2012 | 219 | 0.070 |
Why?
| | Drug Therapy, Combination | 3 | 2014 | 1044 | 0.070 |
Why?
| | Colon | 1 | 2011 | 309 | 0.070 |
Why?
| | Education, Medical, Continuing | 1 | 2009 | 133 | 0.070 |
Why?
| | Emigrants and Immigrants | 1 | 2011 | 157 | 0.070 |
Why?
| | Syphilis, Cutaneous | 1 | 2007 | 3 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2012 | 892 | 0.070 |
Why?
| | Dendritic Cells | 1 | 2011 | 499 | 0.070 |
Why?
| | Specimen Handling | 1 | 2009 | 182 | 0.060 |
Why?
| | Hepacivirus | 1 | 2009 | 242 | 0.060 |
Why?
| | Plasma | 1 | 2009 | 223 | 0.060 |
Why?
| | B-Lymphocytes | 1 | 2012 | 870 | 0.060 |
Why?
| | Risk Assessment | 3 | 2019 | 3747 | 0.060 |
Why?
| | Treatment Outcome | 6 | 2024 | 11772 | 0.060 |
Why?
| | Young Adult | 3 | 2021 | 14218 | 0.060 |
Why?
| | Hepatitis C | 1 | 2009 | 256 | 0.060 |
Why?
| | Acetamides | 1 | 2026 | 41 | 0.060 |
Why?
| | Indazoles | 1 | 2026 | 85 | 0.060 |
Why?
| | HIV-2 | 1 | 2005 | 18 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2007 | 1508 | 0.050 |
Why?
| | Dapsone | 2 | 2004 | 8 | 0.050 |
Why?
| | Sex Factors | 1 | 2011 | 2105 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2011 | 1140 | 0.050 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2004 | 43 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2009 | 777 | 0.050 |
Why?
| | Pneumocystis carinii | 1 | 2004 | 12 | 0.050 |
Why?
| | Chronic Disease | 2 | 2012 | 1808 | 0.050 |
Why?
| | Mediastinitis | 1 | 2003 | 3 | 0.050 |
Why?
| | Virulence | 1 | 2005 | 278 | 0.050 |
Why?
| | Vancomycin Resistance | 1 | 2003 | 16 | 0.050 |
Why?
| | Enterococcus faecium | 1 | 2003 | 22 | 0.050 |
Why?
| | Delayed-Action Preparations | 1 | 2024 | 189 | 0.050 |
Why?
| | Wound Healing | 1 | 2005 | 355 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 305 | 0.050 |
Why?
| | Liver Failure | 1 | 2002 | 83 | 0.040 |
Why?
| | Biopsy | 1 | 2005 | 1082 | 0.040 |
Why?
| | Cryptococcosis | 1 | 2001 | 31 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2002 | 418 | 0.040 |
Why?
| | Dental Care | 1 | 2021 | 25 | 0.040 |
Why?
| | Intracranial Hypertension | 1 | 2001 | 42 | 0.040 |
Why?
| | Coronary Disease | 2 | 2003 | 381 | 0.040 |
Why?
| | Blood | 2 | 2012 | 107 | 0.040 |
Why?
| | Naphthoquinones | 1 | 2001 | 20 | 0.040 |
Why?
| | Cytochrome b Group | 1 | 2001 | 22 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2021 | 123 | 0.040 |
Why?
| | Mutation | 2 | 2004 | 4075 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2005 | 645 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 7123 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2021 | 130 | 0.040 |
Why?
| | Meningitis | 1 | 2001 | 80 | 0.040 |
Why?
| | Renal Insufficiency | 1 | 2002 | 172 | 0.040 |
Why?
| | Neutropenia | 1 | 2001 | 154 | 0.040 |
Why?
| | Antifungal Agents | 1 | 2001 | 151 | 0.040 |
Why?
| | Trust | 1 | 2021 | 155 | 0.040 |
Why?
| | Prospective Studies | 1 | 2012 | 8057 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2021 | 219 | 0.040 |
Why?
| | Anemia | 1 | 2001 | 191 | 0.040 |
Why?
| | JC Virus | 1 | 2019 | 23 | 0.040 |
Why?
| | Spinal Diseases | 1 | 1999 | 50 | 0.040 |
Why?
| | Polyomavirus Infections | 1 | 2019 | 30 | 0.040 |
Why?
| | Boston | 1 | 2019 | 93 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2005 | 769 | 0.040 |
Why?
| | Asymptomatic Infections | 1 | 2019 | 37 | 0.040 |
Why?
| | Abscess | 1 | 1999 | 77 | 0.040 |
Why?
| | Polymerase Chain Reaction | 3 | 2011 | 1041 | 0.040 |
Why?
| | Esophageal Stenosis | 1 | 1999 | 60 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2026 | 1505 | 0.040 |
Why?
| | Training Support | 1 | 2018 | 35 | 0.030 |
Why?
| | Insurance, Health | 1 | 2021 | 310 | 0.030 |
Why?
| | Benchmarking | 1 | 2019 | 191 | 0.030 |
Why?
| | Preceptorship | 1 | 2018 | 63 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2021 | 321 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2001 | 1368 | 0.030 |
Why?
| | Heart-Assist Devices | 1 | 2003 | 568 | 0.030 |
Why?
| | Substance Abuse Detection | 1 | 2019 | 110 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2019 | 184 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 412 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2021 | 709 | 0.030 |
Why?
| | Hospitals, Public | 1 | 2017 | 30 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 782 | 0.030 |
Why?
| | Prenatal Care | 1 | 2019 | 309 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 1082 | 0.030 |
Why?
| | Medicare | 1 | 2022 | 903 | 0.030 |
Why?
| | Ultracentrifugation | 1 | 2016 | 50 | 0.030 |
Why?
| | Postpartum Period | 1 | 2019 | 373 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 83 | 0.030 |
Why?
| | Needs Assessment | 1 | 2018 | 402 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1547 | 0.030 |
Why?
| | Virion | 1 | 2016 | 108 | 0.030 |
Why?
| | Stents | 1 | 1999 | 564 | 0.030 |
Why?
| | Motivational Interviewing | 1 | 2016 | 121 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2019 | 586 | 0.030 |
Why?
| | Neopterin | 1 | 2014 | 13 | 0.030 |
Why?
| | Darunavir | 1 | 2014 | 20 | 0.030 |
Why?
| | Atazanavir Sulfate | 1 | 2014 | 42 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 899 | 0.030 |
Why?
| | Ritonavir | 1 | 2014 | 75 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 848 | 0.020 |
Why?
| | Antigens, CD | 1 | 2016 | 558 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1747 | 0.020 |
Why?
| | Biomarkers | 2 | 2016 | 4295 | 0.020 |
Why?
| | Blood Proteins | 1 | 2014 | 239 | 0.020 |
Why?
| | Qualitative Research | 1 | 2020 | 1674 | 0.020 |
Why?
| | Transplantation | 1 | 2012 | 33 | 0.020 |
Why?
| | Smoking | 1 | 2019 | 1472 | 0.020 |
Why?
| | Inpatients | 1 | 2016 | 553 | 0.020 |
Why?
| | Rifabutin | 1 | 2011 | 7 | 0.020 |
Why?
| | Clarithromycin | 1 | 2011 | 24 | 0.020 |
Why?
| | Ofloxacin | 1 | 2011 | 17 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2012 | 208 | 0.020 |
Why?
| | Integrins | 1 | 2011 | 90 | 0.020 |
Why?
| | Macaca mulatta | 1 | 2011 | 186 | 0.020 |
Why?
| | Hypertension | 1 | 2019 | 1273 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 3204 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2012 | 368 | 0.020 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2012 | 265 | 0.020 |
Why?
| | RNA, Viral | 1 | 2014 | 692 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1371 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2011 | 202 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 749 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1179 | 0.020 |
Why?
| | Health Promotion | 1 | 2015 | 775 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2016 | 4148 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2007 | 61 | 0.020 |
Why?
| | Feces | 1 | 2011 | 495 | 0.020 |
Why?
| | Protein Binding | 1 | 2014 | 2238 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1162 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2011 | 1132 | 0.020 |
Why?
| | Neoplasms | 1 | 2002 | 2906 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 2187 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 7202 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1767 | 0.010 |
Why?
| | Genotype | 1 | 2009 | 1852 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2012 | 1996 | 0.010 |
Why?
| | Chemoprevention | 1 | 2004 | 92 | 0.010 |
Why?
| | China | 1 | 2004 | 270 | 0.010 |
Why?
| | Infant | 1 | 2016 | 10077 | 0.010 |
Why?
| | Atovaquone | 1 | 2001 | 4 | 0.010 |
Why?
| | Survival | 1 | 2001 | 38 | 0.010 |
Why?
| | Child, Preschool | 1 | 2016 | 11853 | 0.010 |
Why?
| | Ubiquinone | 1 | 2001 | 35 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3413 | 0.010 |
Why?
| | Gene Amplification | 1 | 2001 | 118 | 0.010 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2003 | 356 | 0.010 |
Why?
| | Sulfones | 1 | 2000 | 127 | 0.010 |
Why?
| | Epidural Space | 1 | 1999 | 17 | 0.010 |
Why?
| | Postoperative Complications | 2 | 2003 | 2970 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 1999 | 222 | 0.010 |
Why?
| | Animals | 2 | 2011 | 38030 | 0.010 |
Why?
| | Recurrence | 1 | 2001 | 1138 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2001 | 614 | 0.010 |
Why?
| | Radiation Injuries | 1 | 1999 | 149 | 0.010 |
Why?
| | Esophagus | 1 | 1999 | 262 | 0.010 |
Why?
| | Heart Transplantation | 1 | 2003 | 680 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2001 | 2883 | 0.010 |
Why?
| | Child | 1 | 2016 | 22707 | 0.010 |
Why?
| | Esophageal Neoplasms | 1 | 1999 | 348 | 0.010 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1999 | 641 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2003 | 5423 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2001 | 3623 | 0.010 |
Why?
| | Angina Pectoris | 1 | 1971 | 76 | 0.010 |
Why?
| | Coronary Vessels | 1 | 1971 | 246 | 0.000 |
Why?
| | Tomography, X-Ray Computed | 1 | 1999 | 2769 | 0.000 |
Why?
| | Aorta | 1 | 1971 | 440 | 0.000 |
Why?
| | Magnetic Resonance Imaging | 1 | 1999 | 3904 | 0.000 |
Why?
| | Angiocardiography | 1 | 1971 | 1 | 0.000 |
Why?
| | Methods | 1 | 1971 | 68 | 0.000 |
Why?
| | Extracorporeal Circulation | 1 | 1971 | 14 | 0.000 |
Why?
| | Saphenous Vein | 1 | 1971 | 37 | 0.000 |
Why?
| | Transplantation, Autologous | 1 | 1971 | 300 | 0.000 |
Why?
| | Emergencies | 1 | 1971 | 174 | 0.000 |
Why?
|
|
Armstrong's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|